Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity
Suah Yang, Man Kyu Shim, Woo Jun Kim, Jiwoong Choi, Gi‐Hoon Nam, Jeongrae Kim, Jinseong Kim, Yujeong Moon, Han Young Kim, Jooho Park, Yoon Park, In-San Kim, Ju Hee Ryu, Kwangmeyung Kim
Topics & Concepts
DoxorubicinProdrugCancer cellImmunogenic cell deathCytotoxicityCancer researchChemoimmunotherapyPharmacologyImmune systemTumor microenvironmentCytotoxic T cellCancerChemistryImmunotherapyChemotherapyMedicineIn vitroImmunologyBiochemistryInternal medicineNanoparticle-Based Drug DeliveryNanoplatforms for cancer theranosticsPeptidase Inhibition and Analysis